Chardan Capital reiterated their buy rating on shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) in a research report report published on Friday morning. They currently have a $10.00 target price on the stock.

Separately, Guggenheim restated a buy rating and issued a $12.00 target price on shares of Aralez Pharmaceuticals in a report on Monday, August 15th.

Shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 5.64 on Friday. Aralez Pharmaceuticals has a 1-year low of $3.10 and a 1-year high of $10.19. The company’s market cap is $367.96 million. The firm has a 50-day moving average price of $4.78 and a 200 day moving average price of $4.17.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.08. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. The firm earned $12.60 million during the quarter, compared to analyst estimates of $9.70 million. Aralez Pharmaceuticals’s revenue was up 142.3% compared to the same quarter last year. On average, equities analysts anticipate that Aralez Pharmaceuticals will post ($1.05) earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. JW Asset Management LLC raised its stake in shares of Aralez Pharmaceuticals by 49.1% in the second quarter. JW Asset Management LLC now owns 2,737,140 shares of the company’s stock worth $9,033,000 after buying an additional 900,765 shares during the period. Deerfield Management Co. acquired a new stake in shares of Aralez Pharmaceuticals during the first quarter worth approximately $5,838,000. Janus Capital Management LLC raised its stake in shares of Aralez Pharmaceuticals by 1.3% in the second quarter. Janus Capital Management LLC now owns 1,603,757 shares of the company’s stock worth $5,292,000 after buying an additional 20,623 shares during the period. Elk Creek Partners LLC raised its stake in shares of Aralez Pharmaceuticals by 8.8% in the second quarter. Elk Creek Partners LLC now owns 1,514,918 shares of the company’s stock worth $2,518,000 after buying an additional 122,172 shares during the period. Finally, Tiger Legatus Capital Management LLC raised its stake in shares of Aralez Pharmaceuticals by 17.6% in the second quarter. Tiger Legatus Capital Management LLC now owns 1,500,000 shares of the company’s stock worth $4,950,000 after buying an additional 225,000 shares during the period. Institutional investors own 49.63% of the company’s stock.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.